Full Press Release Details
Pharmaceuticals Partners with OnQ Consulting for
2B Trials on its Oral Insulin Capsules
signed with South African CRO to Conduct Phase 2B Trials
Israel - April 17, 2008 - Oramed Pharmaceuticals, Inc. (ORMP.OB, www.oramed.com)
announced today the signing of an agreement with OnQ consulting, a clinical
research organization (CRO) located in Johannesburg, South Africa, to conduct
Phase 2B clinical trials on its oral insulin capsules. The study is intended
evaluate the safety, tolerability and efficacy on diabetic type 2 volunteers,
using Oramed's oral insulin capsule. It is anticipated that this study will be
conducted over several months, and the 30 subjects will each receive the
treatment for a period of 6 weeks.
Oramed Pharmaceuticals, Inc:
Pharmaceuticals is an Israel-based company that focuses on the development
oral delivery solutions based on proprietary technology. Diabetes, one of the
most rapidly growing diseases in the world, requires constant and an often
unpleasant monitoring and drug therapy regimen. Oramed is seeking to develop
oral insulin capsule for the treatment of diabetes, and has recently commenced
Phase 1B of its clinical trials. The company is also pursuing the development
oral delivery solutions for other drugs and vaccines. For more information
Oramed Pharmaceuticals please visit our website at www.oramed.com.
Consulting is a full service CRO based in South Africa. Started nine years
OnQ offers services such as protocol conception and design, project management,
monitoring, pharmacoeconomics and pharmacovigilance, data management,
biostatistical services, and report writing. OnQ Consulting has an established
client base from the CRO, pharmaceutical, NGO and biotech sectors, and is able
to conduct clinical trials internationally through reputable collaborations.
more information, please visit their website at www.onqsa.co.za.
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties, and other factors which
may cause the actual results, performance or achievements of the company,
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company's ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company's filings with the Securities and Exchange commission for a
comprehensive list of risk factors that could
cause actual results, performance or achievements of the company to differ
materially from those expressed or implied in such forward looking statements.
The company undertakes no obligation to update or revise any forward-looking
Pharmaceuticals, Inc
Granito, Steve Melfi